BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute for Bioengineering of Catalonia - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute for Bioengineering of Catalonia
X-ORIGINAL-URL:https://ibecbarcelona.eu
X-WR-CALDESC:Events for Institute for Bioengineering of Catalonia
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20150101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20160527T100000
DTEND;TZID=UTC:20160527T110000
DTSTAMP:20260507T115900
CREATED:20160415T062711Z
LAST-MODIFIED:20160520T055544Z
UID:22419-1464343200-1464346800@ibecbarcelona.eu
SUMMARY:PhD Discussion Session: Elisabet Martí and Maria Valls
DESCRIPTION:Amphoteric polyamidoamines as innovative tools to selectively direct antimalarial drug towards Plasmodium-infected red blood cells\nElisabet Martí\, Nanomalaria joint group\nMalaria\, caused by the protist Plasmodium spp.\, in 2015 alone claimed the lives of more than 400\,000 people\, mainly young African children\, and it had been responsible for 214 million new cases. Despite a significant decrease in the number of malaria-related deaths\, there is still a need for new therapeutic strategies such as finding new antimalarial drugs or substantially improving old ones\, by decreasing side effects and avoiding resistance appearance. The development of highly specific and efficient targeted nanocarriers can be the engine of this change\, which however needs to be done at an affordable cost for malaria endemic countries. \nFour different polyamidoamine (PAA) polymers are being studied in our group with the aim of developing a targeted nanovector capable of reaching in the mid term the preclinical pipeline. \nThe PAA AGMA1 had shown in previous studies antimalarial activity per se at non-toxic concentrations\, as well as certain specificity for pRBCs vs. RBCs. We are trying to elucidate the corresponding mechanisms by characterizing the interaction between AGMA1 and pRBCs. Experiments such as targeting and growth inhibition assays in vitro\, antimalarial activity in vivo and determination of encapsulation capacity are being currently performedwith AGMA1and with three other PAAs: ISA23\, ISA1 and ARGO7. Preliminary results suggest the capacity of AGMA1 to activate the immune system\, indicating that PAAs could be eventually used as an agent with double activity as a drug nanocarrier and as a prophylactic agent. \n  \nDevelopment of a Biomimetic Bioreactor for Cardiac Tissue Engineering Applications\nMaria Valls\, Biomimetic systems for cell engineering group\nIschemic heart disease is a major cause of human death worldwide owing to the heart’s minimal ability to repair following injury. Therefore\, shedding light on heart regeneration and its possible application in medicine is of paramount interest for the scientific community. In this sense\, cardiac tissue engineering aims at obtaining cardiac patches for regenerative medicine purposes. In addition\, these patches could serve as valuable in vitro models to study heart development and regeneration\, heart diseases or as drug screening platforms. \nA prerequisite for obtaining faithful cardiac patches is to mimic the native cardiac environment. Although major advances have been done\, the generation of mature tissue constructs from human induced pluripotent stem (hiPS) cells is still a challenge. To address this\, we have developed a parallelized perfusion bioreactor system and characterized a collagen-based 3D scaffold. Also\, we have designed a perfusion chamber including graphite electrodes to electrically stimulate cells during culture. With this setup\, we have obtained contractile cardiac tissue constructs from primary cultures of neonatal rat heart ventricles that show an enhanced response when cultured under electrical stimulation. \nWe are currently culturing cardiac progenitors derived from hiPS cells\, to produce useful human cardiac tissue surrogates to study cardiovascular tissue maturation as well as for drug/toxicity testing.
URL:https://ibecbarcelona.eu/event/phd-discussion-session-elisabet-marti-and-maria-valls/
CATEGORIES:PhD Discussions Session
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20160527T100000
DTEND;TZID=UTC:20160527T110000
DTSTAMP:20260507T115900
CREATED:20160415T062711Z
LAST-MODIFIED:20160415T062711Z
UID:95907-1464343200-1464346800@ibecbarcelona.eu
SUMMARY:PhD Discussion Session: Elisabet Martí and Maria Valls
DESCRIPTION:Amphoteric polyamidoamines as innovative tools to selectively direct antimalarial drug towards Plasmodium-infected red blood cells\nElisabet Martí\, Nanomalaria joint group\nMalaria\, caused by the protist Plasmodium spp.\, in 2015 alone claimed the lives of more than 400\,000 people\, mainly young African children\, and it had been responsible for 214 million new cases. Despite a significant decrease in the number of malaria-related deaths\, there is still a need for new therapeutic strategies such as finding new antimalarial drugs or substantially improving old ones\, by decreasing side effects and avoiding resistance appearance. The development of highly specific and efficient targeted nanocarriers can be the engine of this change\, which however needs to be done at an affordable cost for malaria endemic countries. \nFour different polyamidoamine (PAA) polymers are being studied in our group with the aim of developing a targeted nanovector capable of reaching in the mid term the preclinical pipeline. \nThe PAA AGMA1 had shown in previous studies antimalarial activity per se at non-toxic concentrations\, as well as certain specificity for pRBCs vs. RBCs. We are trying to elucidate the corresponding mechanisms by characterizing the interaction between AGMA1 and pRBCs. Experiments such as targeting and growth inhibition assays in vitro\, antimalarial activity in vivo and determination of encapsulation capacity are being currently performedwith AGMA1and with three other PAAs: ISA23\, ISA1 and ARGO7. Preliminary results suggest the capacity of AGMA1 to activate the immune system\, indicating that PAAs could be eventually used as an agent with double activity as a drug nanocarrier and as a prophylactic agent. \n  \nDevelopment of a Biomimetic Bioreactor for Cardiac Tissue Engineering Applications\nMaria Valls\, Biomimetic systems for cell engineering group\nIschemic heart disease is a major cause of human death worldwide owing to the heart’s minimal ability to repair following injury. Therefore\, shedding light on heart regeneration and its possible application in medicine is of paramount interest for the scientific community. In this sense\, cardiac tissue engineering aims at obtaining cardiac patches for regenerative medicine purposes. In addition\, these patches could serve as valuable in vitro models to study heart development and regeneration\, heart diseases or as drug screening platforms. \nA prerequisite for obtaining faithful cardiac patches is to mimic the native cardiac environment. Although major advances have been done\, the generation of mature tissue constructs from human induced pluripotent stem (hiPS) cells is still a challenge. To address this\, we have developed a parallelized perfusion bioreactor system and characterized a collagen-based 3D scaffold. Also\, we have designed a perfusion chamber including graphite electrodes to electrically stimulate cells during culture. With this setup\, we have obtained contractile cardiac tissue constructs from primary cultures of neonatal rat heart ventricles that show an enhanced response when cultured under electrical stimulation. \nWe are currently culturing cardiac progenitors derived from hiPS cells\, to produce useful human cardiac tissue surrogates to study cardiovascular tissue maturation as well as for drug/toxicity testing.
URL:https://ibecbarcelona.eu/event/phd-discussion-session-elisabet-marti-and-maria-valls-2/
CATEGORIES:PhD Discussions Session
END:VEVENT
END:VCALENDAR